$3.79 +0.11 (%) Xoma Corp - NASDAQ

Mar. 5, 2015 | 09:50 AM

Partner Headlines

  1. US Stock Futures Edge Lower Ahead Of Auto Sales

    Benzinga | Mar. 3, 2015 | 07:53AM EST
  2. Morning Market Gainers

    Benzinga | Mar. 2, 2015 | 09:45AM EST
  3. Benzinga's Top #PreMarket Gainers

    Benzinga | Mar. 2, 2015 | 08:11AM EST
  4. XOMA Announces Pricing Of $40.0M Registered Offering Of Common Stock And Warrants

    Benzinga | Dec. 9, 2014 | 09:02AM EST
  5. Here's The Last Biotech Breakout

    Benzinga | Nov. 26, 2014 | 12:01PM EST
  6. XOMA Corp Volatile Amid Differing Analyst Reports

    Benzinga | Nov. 10, 2014 | 11:45AM EST
  7. XOMA Launches XOMA 358 Clinical Development

    Benzinga | Oct. 9, 2014 | 09:22AM EST
  8. XOMA Licensing Manufacturing Tech To Texas A&M, No Terms Disclosed

    Benzinga | Oct. 6, 2014 | 13:05PM EST
  9. XOMA Initiates U.S. Clinical Trial of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD - US

    Benzinga | Sep. 30, 2014 | 16:06PM EST
  10. MLV & Co Has Positive Outlook On XOMA

    Benzinga | Aug. 8, 2014 | 10:00AM EST
  11. Morning Market Movers

    Benzinga | Apr. 29, 2014 | 09:43AM EST
  12. UPDATE: MLV & Co Upgrades XOMA on Valuation

    Benzinga | Apr. 29, 2014 | 07:56AM EST
  13. XOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum

    Benzinga | Apr. 28, 2014 | 09:03AM EST
  14. Benzinga's Top Downgrades

    Benzinga | Mar. 11, 2014 | 08:35AM EST
  15. UPDATE: MLV & Co Downgrades XOMA on Valuation/Sentiment

    Benzinga | Mar. 11, 2014 | 08:14AM EST
  16. Mid-Afternoon Market Update: FuelCell Energy Hangs on to Gains as Canadian Solar Shares Fall on Poor Report

    Benzinga | Mar. 5, 2014 | 15:27PM EST
  17. Mid-Day Market Update: Smith & Wesson Surges On Upbeat Results; XOMA Shares Drop

    Benzinga | Mar. 5, 2014 | 13:19PM EST
  18. Mid-Morning Market Update: Markets Mostly Flat; Brown-Forman Posts Higher Profit

    Benzinga | Mar. 5, 2014 | 10:22AM EST
  19. Morning Lowers for Mar. 5, 2014: XOMA, USU, CSIQ, AUDC, RATE

    Benzinga | Mar. 5, 2014 | 10:14AM EST
  20. Benzinga's Top #PreMarket Losers

    Benzinga | Mar. 5, 2014 | 08:13AM EST
  21. UPDATE: XOMA Offers Update on Gevokizumaba, Says Results Do Not Support Movement to Pivotal Development Trial

    Benzinga | Mar. 4, 2014 | 16:42PM EST
  22. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

    Benzinga | Feb. 25, 2014 | 09:41AM EST
  23. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 13, 2014 | 10:50AM EST
  24. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 2, 2014 | 08:20AM EST
  25. XOMA Announces Closing of the Offering and Exercise of 1.425M Share Over Allotment Option

    Benzinga | Dec. 18, 2013 | 16:04PM EST
  26. XOMA Announces Pricing of 9.5M Shares at $5.25 per Share

    Benzinga | Dec. 13, 2013 | 09:15AM EST
  27. XOMA Prices 9.5M Share Offering at $5.25/Share

    Benzinga | Dec. 13, 2013 | 09:15AM EST
  28. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 13, 2013 | 08:38AM EST
  29. Benzinga's Top #PreMarket Gainers

    Benzinga | Oct. 31, 2013 | 08:13AM EST
  30. Xoma Shares Rise 6% After-Hours on Encouraging Phase 2 Gevokizumab Results

    Benzinga | Oct. 30, 2013 | 16:57PM EST
  31. XOMA Shares Quiet Following Results of Two Phase 2 Trials Showing Gevokizumab Program 'Very Encouraging,' 'Compelling'

    Benzinga | Oct. 30, 2013 | 16:50PM EST
  32. UPDATE: Piper Jaffray Initiates XOMA at Overweight on 'Xciting Antibody Play'

    Benzinga | Aug. 13, 2013 | 08:40AM EST
  33. Benzinga's Top Initiations

    Benzinga | Aug. 13, 2013 | 08:10AM EST
  34. Benzinga's Top Pre-Market Losers

    Benzinga | Feb. 4, 2013 | 01:22AM EST
  35. UPDATE: Wedbush Raises PT to $5 on Xoma on Gevokizumab Initial Efficacy

    Benzinga | Jan. 7, 2013 | 07:14AM EST
  36. XOMA Says Sevier Initiated Proof-of-Concept Gevokizumab Study for Acute Coronary Syndrome Patients

    Benzinga | Nov. 29, 2012 | 01:25AM EST
  37. XOMA Corp (XOMA) CFO & VP Finance Fred Kurland sells 9,111 Shares

    GuruFocus | Nov. 15, 2012 | 04:35AM EST
  38. XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis

    Benzinga | Sep. 27, 2012 | 07:15AM EST
  39. UPDATE: XOMA Receives Orphan Drug Designation From FDA for Gevokizumab

    Benzinga | Aug. 22, 2012 | 10:55AM EST
  40. XOMA Ltd. Reports Operating Results (10-Q)

    GuruFocus | Aug. 7, 2012 | 13:33PM EST
  41. CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility; Terms Not Disclosed

    Benzinga | Jul. 31, 2012 | 02:04AM EST
  42. Oncobiologics Announces Agreement To Utilize XOMA's Fully Human Antibody Libraries For Discovery Platform

    Benzinga | Jul. 30, 2012 | 04:08AM EST
  43. Health Care Sector Wrap

    FoxBusiness | Jul. 6, 2012 | 10:51AM EST
  44. Benzinga's Top Initiations

    Benzinga | Jun. 28, 2012 | 01:51AM EST
  45. Earnings Scheduled For March 6

    Benzinga | Mar. 5, 2012 | 20:58PM EST
  46. End-of-Day Market Summary for January 17, 2012

    Benzinga | Jan. 17, 2012 | 09:16AM EST
  47. Xoma Shares Down After Job Cuts and One Time Charges Announced

    Benzinga | Jan. 13, 2012 | 06:05AM EST
  48. Benzinga's Microcap Movers for Thursday January 5, 2012

    Benzinga | Jan. 5, 2012 | 13:24PM EST
  49. XOMA Streamlines Operations to Invest in Value-Creating Activities; Cuts 34% of Workforce

    Benzinga | Jan. 5, 2012 | 05:45AM EST
  50. XOMA Corporation New CEO Says Company Expects to Initiate Global Gevokizumab Phase 3 Program in Q2 of 2012

    Benzinga | Jan. 5, 2012 | 05:38AM EST
Trading Center